RU2006105646A - Производные азепина в качестве фармацевтических агентов - Google Patents

Производные азепина в качестве фармацевтических агентов Download PDF

Info

Publication number
RU2006105646A
RU2006105646A RU2006105646/04A RU2006105646A RU2006105646A RU 2006105646 A RU2006105646 A RU 2006105646A RU 2006105646/04 A RU2006105646/04 A RU 2006105646/04A RU 2006105646 A RU2006105646 A RU 2006105646A RU 2006105646 A RU2006105646 A RU 2006105646A
Authority
RU
Russia
Prior art keywords
optionally substituted
heteroaryl
heterocyclyl
ring
alkyl
Prior art date
Application number
RU2006105646/04A
Other languages
English (en)
Russian (ru)
Inventor
Ричард МАРТИН (US)
Ричард Мартин
Те-Линь ВАН (US)
Те-Линь ВАН
Брентон Т. ФЛЭТТ (US)
Брентон Т. ФЛЭТТ
С о-Хой ГУ (US)
Сяо-Хой ГУ
Original Assignee
Экселиксис, Инк. (Us)
Экселиксис, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Экселиксис, Инк. (Us), Экселиксис, Инк. filed Critical Экселиксис, Инк. (Us)
Publication of RU2006105646A publication Critical patent/RU2006105646A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU2006105646/04A 2003-07-23 2004-07-23 Производные азепина в качестве фармацевтических агентов RU2006105646A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48985403P 2003-07-23 2003-07-23
US60/489,854 2003-07-23

Publications (1)

Publication Number Publication Date
RU2006105646A true RU2006105646A (ru) 2007-09-10

Family

ID=34102943

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006105646/04A RU2006105646A (ru) 2003-07-23 2004-07-23 Производные азепина в качестве фармацевтических агентов

Country Status (14)

Country Link
US (1) US8466143B2 (enExample)
EP (1) EP1648408A4 (enExample)
JP (1) JP4679517B2 (enExample)
KR (1) KR20060052867A (enExample)
CN (1) CN1852748A (enExample)
AU (1) AU2004259009A1 (enExample)
BR (1) BRPI0412262A (enExample)
CA (1) CA2532798C (enExample)
CR (1) CR8258A (enExample)
EC (1) ECSP066392A (enExample)
IL (1) IL173287A0 (enExample)
NO (1) NO20060871L (enExample)
RU (1) RU2006105646A (enExample)
WO (1) WO2005009387A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595311B2 (en) * 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
AU2004283196B2 (en) 2003-09-17 2011-08-25 Janssen Pharmaceutica, N.V. Fused heterocyclic compounds
EP1858900B1 (en) 2005-03-14 2009-01-07 Glaxo Group Limited Fused thiazole derivatives having affinity for the histamine h3 receptor
WO2007070796A1 (en) * 2005-12-15 2007-06-21 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
US20080299118A1 (en) * 2007-06-01 2008-12-04 Wyeth FXR Agonists for the Treatment of Malignancies
US20080300235A1 (en) * 2007-06-01 2008-12-04 Wyeth FXR Agonists for Reducing LOX-1 Expression
US20090163474A1 (en) * 2007-10-19 2009-06-25 Wyeth FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases
US20090215748A1 (en) * 2007-12-20 2009-08-27 Wyeth FXR agonists for treating vitamin D associated diseases
EP2348847A4 (en) 2008-10-31 2012-05-23 Medivation Technologies Inc AZEPINO [4, 5-B] INDOLE AND USE PROCESS
CN102271508B (zh) 2008-10-31 2015-04-29 梅迪维新技术公司 含有刚性部分的吡啶并[4，3-b]吲哚类化合物
CN101875627B (zh) * 2009-04-30 2014-01-15 凯惠科技发展(上海)有限公司 一种1-烷氧羰基-2h-异吲哚衍生物及其制备方法和中间体
AU2010249472B2 (en) 2009-05-22 2015-09-10 AbbVie Deutschland GmbH & Co. KG Modulators of 5-HT receptors and methods of use thereof
US9034865B2 (en) 2010-02-18 2015-05-19 Medivation Technologies, Inc. Pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
US9193728B2 (en) 2010-02-18 2015-11-24 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
WO2011103485A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
WO2011146089A1 (en) 2010-05-21 2011-11-24 Abbott Laboratories Modulators of 5-ht receptors and methods of use thereof
US20140303144A1 (en) * 2011-02-18 2014-10-09 Medivation Technologies, Inc. Compounds and methods of treating hypertension
CN103476416B (zh) 2011-02-18 2016-09-21 梅迪维新技术公司 治疗高血压的化合物和方法
EP2887805A4 (en) * 2012-08-22 2016-08-17 Medivation Technologies Inc COMPOUNDS AND METHOD FOR TREATING BLOOD HIGH PRESSURE
MX370480B (es) 2014-11-21 2019-12-16 Akarna Therapeutics Ltd Compuestos bicíclicos fusionados para el tratamiento de enfermedades.
MX369623B (es) * 2014-12-22 2019-11-14 Akarna Therapeutics Ltd Compuestos biciclicos fusionados para el tratamiento de enfermedades.
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
WO2016151403A1 (en) 2015-03-26 2016-09-29 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
WO2017143134A1 (en) * 2016-02-19 2017-08-24 Alios Biopharma, Inc. Fxr modulators and methods of their use
BR112018074231A2 (pt) * 2016-05-25 2019-03-06 Akarna Therapeutics, Ltd. compostos bicíclicos fundidos para o tratamento de doença
CA3025007A1 (en) * 2016-05-25 2017-11-30 Akarna Therapeutics, Ltd. Combination therapies with farnesoid x receptor (fxr) modulators
CA3065313A1 (en) * 2017-06-02 2018-12-06 Akarna Therapeutics, Ltd. Fused bicyclic compounds
AU2019212800B2 (en) * 2018-01-26 2024-05-23 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
SG11202006945PA (en) 2018-01-26 2020-08-28 Exelixis Inc Compounds for the treatment of kinase-dependent disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR35044B (el) 1966-05-10 1968-07-31 The Upjohn Company Μεθοδος παρασκευης οργανικων ενωσεων.
US4362739A (en) * 1981-05-04 1982-12-07 S.A. Omnichem Pyrrolo(2,3-d)carbazole derivatives, compositions and use
IL101851A (en) * 1991-06-13 1996-05-14 Janssen Pharmaceutica Nv 10-(4-piperidinyl- and piperidinylidene)-imidazo [1,2-a] (pyrrolo thieno or furano) [2,3] azepine derivatives their preparation and pharmaceutical compositions containing them and certain novel intermediates therefor
JPH09221475A (ja) * 1996-02-13 1997-08-26 Yamanouchi Pharmaceut Co Ltd 新規なオキシム誘導体
AU8766498A (en) * 1997-08-04 1999-02-22 Amgen, Inc. Hydroxamic acid substituted fused heterocyclic metalloproteinase inhibitors
WO2000078972A2 (en) 1999-06-18 2000-12-28 Cv Therapeutics, Inc. Regulation with binding cassette transporter protein abc1
FR2796070B1 (fr) * 1999-07-06 2003-02-21 Lipha Derives de benzodiazepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparation
MY122278A (en) * 1999-07-19 2006-04-29 Upjohn Co 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position
US20020013334A1 (en) * 2000-06-15 2002-01-31 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
US7595311B2 (en) * 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
WO2007070796A1 (en) * 2005-12-15 2007-06-21 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents

Also Published As

Publication number Publication date
JP2006528637A (ja) 2006-12-21
BRPI0412262A (pt) 2006-09-19
ECSP066392A (enExample) 2007-01-26
NO20060871L (no) 2006-04-24
IL173287A0 (en) 2006-06-11
US8466143B2 (en) 2013-06-18
CA2532798C (en) 2013-02-19
WO2005009387A3 (en) 2006-03-02
EP1648408A4 (en) 2006-11-29
US20070015746A1 (en) 2007-01-18
JP4679517B2 (ja) 2011-04-27
WO2005009387A2 (en) 2005-02-03
CA2532798A1 (en) 2005-02-03
EP1648408A1 (en) 2006-04-26
CR8258A (es) 2006-08-30
KR20060052867A (ko) 2006-05-19
AU2004259009A1 (en) 2005-02-03
CN1852748A (zh) 2006-10-25

Similar Documents

Publication Publication Date Title
RU2006105646A (ru) Производные азепина в качестве фармацевтических агентов
JP2006528637A5 (enExample)
JP4217968B2 (ja) 三環式複素環誘導体化合物およびその化合物を有効成分とする医薬
CN102197038B (zh) 用于治疗自身免疫性病症和炎性病症的作为s1p1受体激动剂的经取代的三环酸衍生物
CN119033782B (zh) 抗血小板药物和其用途
CA2886710A1 (en) 2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders
EP1161434A1 (fr) Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique
AU2007311983A1 (en) An Alzheimer' s disease progression inhibitor containing heterocyclic compound
CZ20014178A3 (cs) Nové deriváty a analogy galanthaminu
AU2018235266A1 (en) Pharmacologically active alicyclic-substituted pyrazolo[1,5-a]pyrimidine derivatives
HU204053B (en) Process for producing eseroline derivatives and pharmaceutical compositions comprising such compounds as active ingredient
JP5898233B2 (ja) 置換された水素化チエノ−ピロロ［３，２−ｃ］ピリジン、リガンド、医薬組成物及び上記を使用するための方法
FR2859208A1 (fr) Nouveaux derives de 9-amino-podophyllotoxine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2010076418A1 (fr) Nouveaux dérivés d'oxime du 3,5-seco-4-nor-cholestane, compositions pharmaceutiques les renfermant, et procédé de préparation
KR0183395B1 (ko) 2,4,8-삼치환된 3H,6H-1,4,5a,8a-테트라아자아세나프틸렌-3,5-(4H)-디온화합물, 및 이의 제조방법
AU2021348704A1 (en) Fused tricyclic derivative and pharmaceutical application thereof
IE44809B1 (en) Bis-penicillanoyloxy-alkanes
CZ99394A3 (en) 2,6-disubstituted 4-quinolinyl-dihydropyridines, process of their preparation , medicaments containing said substances, process of their preparation and the use of said compounds
KR20220015426A (ko) 캡시드 조립 조절제로서의 융합 복소환 유도체
WO1993012120A1 (fr) Derive de pyrazolothiazolopyrimidine
FI95242C (fi) Menetelmä pyrrolijohdannaisten diesterien valmistamiseksi ja menetelmässä käyttökelpoiset välituotteet
JP2971901B2 (ja) トリアゾロ―１，４―ジアゼピン系化合物
CA2502488A1 (fr) Nouveaux derives de [1,4]benzodioxino[2,3-e]isoindole substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2101933A1 (en) Neuroprotectant agents
EP4330255A1 (en) Processes for the synthesis of valbenazine

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20100203